Navigation Links
Biolaxy Secures IND Approval for Oral Insulin
Date:11/24/2009

SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.

Diabetes is a disorder characteristic of high blood glucose and poor metabolism. The complications of diabetes often result in severe micro- and macro-vascular diseases, loss of vision, kidney failure, and amputation. Insulin, as an effective diabetic treatment, can slow down diabetic disease progression. However, insulin is given by multiple daily injections at present, which significantly hinders its use.

Oral drug administration is a preferred route. However, the gastrointestinal (GI) tract is designed to digest nutrients like proteins and presents significant challenges for oral insulin including enzyme degradation and poor absorption. Currently, there is no approved oral insulin product despite intensive research in this field.

Nodlin is developed with NOD technology, a patented bio-adhesive nano-particle oral delivery technology, to overcome the barriers of oral insulin.

"IND approval is a significant milestone achievement for Biolaxy," quoted from William Lee, CEO. "We have experienced long delay in the approval process due to regulatory uncertainties, but we are very happy now Biolaxy is back on track in full speed to develop urgently needed drugs for the patients."

    For more information, please contact:

     William Lee, Ph.D., CEO
     Phone: +86-21-6194-0758
     Email: info@biolaxy.com

    Press Contact
     Qianyu Zhao, Ph.D., Director of R&D
     Phone: +86-21-6194-0858 x807
     Email: info@biolaxy.com


    Notes for Editors

About Diabetes and Insulin Treatment

Diabetes has reached epidemic stage. It is estimated that there are 30-40 million diabetic patients in China with 1.2 million new cases each year. Insulin is a key diabetic treatment with worldwide market value close to $10 billion. Diabetic patients have to endure multiple daily injections for life and patients often are reluctant to use insulin despite the clinical proven benefits of early insulin treatment. Currently, insulin treatment in China particularly is under used.

About Biolaxy

Shanghai Biolaxy is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. Biolaxy was established in 2005 and is a wholly owned subsidiary of NOD Pharmaceuticals. Biolaxy uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

Nodlin is the first candidate developed with NOD technology and is positioned as basal insulin formulation based on the pre-clinical data. Nodlin possesses unique pharmacokinetic profile and is highly competitive.

More information can be found at http://www.biolaxy.com .

SOURCE Shanghai Biolaxy


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Secures 10-Year Tissue Supply Agreement
2. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
3. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
4. LS9 Secures $25 Million in Latest Round of Funding
5. Neurocrine Biosciences Secures Committed Equity Financing Facility
6. OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm
7. Cappella Inc. Secures $17.3 Million Series C Investment
8. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
9. Sinobiopharma Secures Rights to Seven Key Patents
10. Aerovance Secures $38 Million in Equity Financing
11. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... education provider of women’s health, primary care, and specialty education, announced today ... Medical Education (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and ...
(Date:2/22/2017)... 22, 2017 Dublin ... "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, By End ... to their offering. ... Global Biological Crop Protection Market is forecasted to grow at ... growth in biopesticide or biological crop protection market is driven by ...
(Date:2/22/2017)... Switzerland (PRWEB) , ... February 22, 2017 , ... ... ., announced the addition of Tom Perkins as European director. Operating from Pennside’s ... experience to Pennside. , Perkins joins Pennside after more than a decade ...
(Date:2/21/2017)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... months ended December 31, 2016. SQI is ... company that develops and commercializes proprietary technologies and products for ... ... milestones achieved in fiscal 2016," said Andrew Morris , ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/19/2017)... CLARA, Calif. , Jan. 19, 2017 /PRNewswire/ ... company enhancing user experience and security for consumer ... of next-generation payment processing systems and cybersecurity solutions, ... more banks, enterprises and financial institutions worldwide to ... part of the end-to-end secure user authentication platforms ...
Breaking Biology News(10 mins):